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Reversal by a particular metabolite implies that the inhibitor in question prevents growth by interfering with a biochemical pathway involving that metabolite, e. g., its synthesis, utilization, or penetration (see Cowan and Rowatt, 1958 , for general review). The ideal situation, several instances of which have been already described (Foster and Pittillo, 1953b; Pittillo and Foster, 1954) , is where the inhibitor blocks the biosynthesis of the metabolite.
Chemically dissimilar inhibitors whose effects are reversible by the same metabolite probably interfere at different sites on a common pathway. When the two inhibitors are present simultaneously, the effects of each theoretically should be mutually potentiated. Beerstecher and Shive (1947) and Potter (1951) showed how one kind of synergism (sequential blocking) can be achieved by metabolite analogues whose sites of action are known, and where detailed knowledge of the pathways involved is available. This approach to synergism-the combination testing, both in vitro and in vivo, of pairs of metabolite analogueshas been very extensively exploited in recent years. Notwithstanding the discovery of a significant number of synergistically acting combinations (Lacey, 1958) , the great majority of randomly paired analogues do not display this kind of activity. Even biochemically related analogues are not predictably synergistic (Hitchings et al., 1955; Veldstra, 1956) . One is obliged, consequently, to conclude that at the present time one cannot with accuracy predict which metabolite analogue pairs will be synergistic. Although the analogue approach does in some measure predispose success in securing synergism, the procedure basically is one of empirieally screening for random instances of synergism.
The unique feature of the "reversal" technique enables selection of sequential blockers without any prior knowledge of the biosynthetic pathways involved. In each of the several cases where synergism was predicted according to the reversal rationale, it was obtained (Pittillo and Foster, 1954) . The present work extends the number of such illustrations. They stem from the discovery of new instances of metabolite reversal of inhibitors. Theoretical aspects of the reversal approach to inhibitor synergism are also discussed.
MATERIALS AND METHODS
The spread plate procedure described previously (Maas and Davis, 1950; Foster and Pittillo, 1953a) was employed. Briefly, the procedure involves incorporation of graded doses of an inhibitor in melted glucose-salts agar prior to pouring into duplicate petri plates. The concentrations in any series differed by a factor of 2 or 3. After solidification, the agar was inoculated by surface spreading 0.05 ml of a unicellular water suspension containing 50 to 150 twice washed bacteria. The inhibitory concentration is the smallest one which prevents the development of colonies visible to the unaided eye in a specified incubation period (at 37 C) during which control plates without inhibitor produce colonies normal for the particular organism. By "reversal" is meant the development of colonies from all of the cells in the inoculum as a result of the incorporation of a metabolite in the medium con-566 taining an otherwise toxic concentration of inhibitor. In this study, these colonies frequently were somewhat smaller than the control colonies. The concentration of inhibitor required for complete inhibition in the presence of excess metabolite, compared to that in the absence, is called "reversal factor."
High sensitivity, rigorous quantitation, and exclusion of selection of resistors and of nonspecific growth stimulation, ensue from the all or none criterion of growth with respect to the individual cells in the inoculum. These characteristics distinguish the spread plate procedure as a means for evaluating the true reversibility of inhibitors of bacteria.
RESULTS

Metabolite reversal of individual inhibitors.
Most of the present work centers around the discovery that under the test conditions the toxicities of 6-mercaptopurine and riboflavin are counteracted by calcium pantothenate and biotin, respectively (table 1). Although the calcium pantothenate reversal of 6-mercaptopurine was demonstrable with all 3 bacterial cultures on which it was tried, significant quantitative differences were found. In our experience with this procedure, a reversal factor of 100 is large.
6-Mercaptopurine. This is primarily an antipurine compound particularly effective in blocking nucleic acid synthesis in organisms requiring exogenous purines or ribonucleosides; it is also an effective inhibitor of nucleic acid synthesis in mammalian cells. Being a metabolite analogue, 6-mercaptopurine is reversed by one or more physiological purines, nucleosides, and nucleotides (Miner, 1954) . A growing list of instances makes it probable that 6-mercaptopurine also antagonizes the synthesis or utilization of purine-containing coenzymes including diphosphopyridine nucleotide (Kaplan et al., 1956 ) and especially coenzyme A (Biesele, 1955; Tobioka and Biesele, 1956; Garattini et al., 1955; Bolton and Mandel, 1957 Reversal of 6-mercaptopurine inhibition by compounds related to pantothenic acid. The follow- (Perry and Foster, 1956 ). This orange pigmented organism was labeled Bacillus globigii; it has been reclassified as Bacillus subtilis var. niger (Smith et al., 1952 (Ivanovics, 1942; Maas, 1952) . Synergistic inhibition with 6-mercaptopurine. Ribofavin. The high toxicity of riboflavin for E. coli strain B in glucose-salts medium has been discovered (Foster and Pittillo, 1953b) . The compound is also toxic for Mllicrococcus pyogenes var. aureus (Ramsey and Wilson, 1957) and for two of Lochhead and Burton (1955) types of cobalamine-requiring soil bacteria. The soil bacteria also require biotin; in the presence of yeast extract their growth was ascribed to a reversal of riboflavin inhibition by substances in the yeast extract. It remains to be seen if biotin is the active reversing substance, as it is for Bacillus subtilis var. globigii (table 1) .
Synergism experiments with riboflavin. Actithiazic acid and isonicotinic hydrazide, the inhibitory effects of which are known to be reversed by biotin (Grundy et al., 1952; Pittillo and Foster, 1954) have been shown to inhibit the biosynthesis of biotin in A. aerogenes strain P (Pittillo and Foster, 1954 An important practical advantage of the reversing approach, compared with blocking of known sequential reactions, is that neither the site of the inhibition, the mode of action of the inhibitor, nor the step affected in the biosynthesis or utilization of the reversing metabolite needs to be known in order to obtain synergistic inhibitors. The different synergistic combinations affecting the pantothenate pathway illustrate the scope of the reversal method. Thus, a combination of two pantoate inhibitors, 6-mercaptopurine and Na salicylate (Ivanovics, 1942; Maas, 1952) , was obtained; also, a combination of a p-alanine inhibitor, Na propionate or D-serine (Wright and Skeggs, 1946; King and Cheldelin, 1948; Maas and Davis, 1950 ) and a pantoate inhibitor, 6-mercaptopurine. Unfortunately, a combination of Na propionate and D-serine as two /3-alanine inhibitors was not tested for synergism in this work, but synergistic inhibition of pantothenate synthesis by two fl-alanine inhibitors, namely, D-serine and L-aspartate, has been described by Maas and Davis (1950) using the reversal technique.
An interesting corollary of the reversal approach is that two dissimilar inhibitors, each synergistic with the same compound, are apt to be synergistic with each other. For example, isonicotinic hydrazide and actithiazic acid, each synergistic with riboflavin in blocking biotin metabolism, are also synergistic with each other in blocking biotin metabolism (Pittillo and Foster, 1954) . New synergistic combinations should be obtainable among compounds selected solely on the basis of their respective synergistic properties with a common second inhibitor. In the manner described elsewhere (Pan and Foster, 1957) Lowery and Foster (1959) screened antibiotically active filtrates of soil actinomycetes for the property of synergism with azaserine (O-diazoacetyl-iserine). The incidence of synergism among pairs of these selected filtrates was much greater than one would reasonably expect from the occurrence of synergism among unselected inhibitors. In contrast to the relation between a reversing agent and an inhibitor discussed in the foregoing, Davis (1957) has pointed out that compounds that reverse an inhibition are not necessarily metabolites whose synthesis or utilization is stopped by the inhibitor. Such reversing compounds could alternatively be blocking the penetration of an inhibitor into the cell or into a subceliular structure. This could falsely suggest a synergistic combination of inhibitors. However, if such a blocking compound is itself a metabolite, a second inhibitor preventing its synthesis or blocking its function might produce synergism with the first inhibitor.
In addition to factors such as penetrability and properties of affected enzymes (Maas and Davis, 1952; Horowitz and Fling, 1953 ) the intracellular pools of metabolite reversers undoubtedly influence the sensitivity of an organism to an inhibitor. Most inhibitors are reversible to varying degrees by one or more metabolites (Foster and Pittillo, 1953a, b) . It seems probable that the intracellular pool of metabolites, whether of endogenous or exogenous origin, reduces the efficacy of a given concentration of inhibitor. The metabolites represent a kind of internal buffer defending against inhibitors. Reduction in the level of one or more active components of the pool by a second inhibitor should, consequently, render the cell more liable to chemical inhibition ("protected inhibition," Pittillo and Foster, 1954 
